GSK PLC ADRhedged
GSKH
1 hedge funds and large institutions have $6.08K invested in GSK PLC ADRhedged in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
1.33% less ownership
Funds ownership: 1.33% → 0% (-1.3%)
13% less capital invested
Capital invested by funds: $6.99K → $6.08K (-$908)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.81K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $6.08K | -$1.81K | -33 | -25% |
|
GSKH Hedge Fund Activity: Q3 2025 in Review
1 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in GSK PLC ADRhedged (GSKH) for Q3 2025, worth a combined $6.08K — down 13% from $6.99K a quarter earlier.
Fund positioning in GSKH was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $1.81K.
- 1 institutional investor held GSK PLC ADRhedged (GSKH) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $6.08K of GSK PLC ADRhedged stock for Q3 2025, down 13% quarter-over-quarter.
- 0 funds opened new GSK PLC ADRhedged positions in Q3 2025 and 0 closed out.
- The largest GSK PLC ADRhedged seller in Q3 2025 was UBS Group, an estimated $1.81K sold.
Based on aggregated 13F filings for Q3 2025.